

DERMATOLOGY ORDER SET

FAX: 470.922.3656 | PHONE: 470.377.6400

PATIENT INFORMATION:

Fax completed form, insurance information, and clinical documentation to 470.922.3656

Patient	Name [.]
i aucrit	name.

Phone:

DOB:

Patient Status: New to Therapy Continuing Therapy Next Treatment Date:

MEDICAL INFORMATION

Patient Weight: _____ lbs. (required) Allergies: ____

THERAPY ORDER		
Diagnosis	Medication Orders	Refills
Dermatomyositis Dermatopolymyositis Phemphigoid/Pemphigus Other:	IVIg Orders: mg/kg OR gm/kg IV x day(s) OR divided over day(s) Frequency: Every weeks OR Preferred brand: (Biocare Infusion to choose if not indicated) Additional Ig orders:	□x1 year
□ CIU ICD-10:	□ Xolair □ 150mg SQ every 4 weeks □ 300mg SQ every 4 weeks Note: Patient must have an EpiPen in their possession on their appointment date	□x1 year
Pemphigus Vulgaris ICD-10:	Rituximab or rituximab biosimilar as required by patient's insurance Do not substitute. Infuse the following rituximab product: For Biocare Infusion use only. Brand: Initial Dose: 1000mg IV at day 0, 15 days Maintenance Dose: 500mg IV at month 12 and every 6 months thereafter Other dose: Protocol Protocol Premedication Orders: Solu-Medrol 100mg IV, Tylenol 1000mg PO, and Benadryl 50mg PO/IV	□
 Psoriatic Arthritis Psoriasis Plaque Psoriasis ICD-10: 	□ Infliximab or infliximab biosimilar as required by patient's insurance □ Do not substitute. Infuse the following infliximab product:	□x1 year □
Generalized Pustular Psoriasis	 Spevigo 900mg IV x 1 Repeat Spevigo 900mg IV in 1 week if symptoms persist 	
ICD-10:		
Premedication orders: Tylenol 1000mg 500mg PO, please choose one antihistamine: Diphenhydramine 25mg PO Loratadine 10mg PO Cetirizine 10mg PO Quzyttir 10mg IVP Additional premedications: Solu-Medrol mg IVP Solu-Cortef mg IVP Other Lab orders: Frequency: Every infusion Other: Biocare Infusion Referring provider		
PROVIDER INFORMATION		
agent in dealing with medical and prescript Provider Name: Provider NPI:	es, you are authorizing <i>Biocare Infusion</i> , and its employees to serve as your prior authorization and specialty pharmacy designated in insurance companies, and to select the preferred site of care for the patient Date: Date: Date: Date: Signature: Contact Person: Signature: Signature: Contact Person: Date: To selecting site of care (if checked, please list site of care):	_
City:	State: View our locations here:	

BIOCAREINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



COMPREHENSIVE SUPPORT FOR DERMATOLOGY THERAPY

PATIENT INFORMATION:
Patient Name: DOB:
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL
Include signed and completed order (MD/prescriber to complete page 1)
Include patient demographic information and insurance information
Include patient's medication list
Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
For biologic orders, has the patient had a documented contraindication/intolerance or failed trial of a conventional therapy (i.e., steroids)? Yes D No If yes, which drug(s)?
□ For biologic orders, does the patient have a contraindication/intolerance or failed trial to any other biologic (i.e., Stelara, Cimzia)? □ Yes □ No If yes, which drug(s)?
Include labs and/or test results to support diagnosis
If applicable - Last known biological therapy: and last date received: and last date received: If patient is switching to biologic therapies, please perform a wash-out period of weeks prior to starting ordered biologic therapy.
Other medical necessity:
REQUIRED PRE-SCREENING (BASED ON DRUG THERAPY)
□ TB screening test completed within 12 months - attach results Required for: Cimzia, infliximab, Stelara, Ilumya, Simponi Aria, Spevigo □ Positive □ Negative
 Hepatitis B screening (Hepatitis B surface antigen) - Positive Negative Required for: Cimzia, infliximab, rituximab, Simponi Aria Hepatitis B core antibody total (not IgM) - Positive Negative Required for: rituximab
Serum immunoglobulins - attach results Recommended for: rituximab
 Baseline creatinine Required for: IVIG *If TB or Hepatitis B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+) Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.
Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance

BIOCAREINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.